national healthcare corporation - NHC
NHC
Close Chg Chg %
160.08 1.31 0.82%
Closed Market
161.39
+1.31 (0.82%)
Volume: 63.55K
Last Updated:
Feb 6, 2026, 3:59 PM EDT
Company Overview: national healthcare corporation - NHC
NHC Key Data
| Open $158.44 | Day Range 158.44 - 163.11 |
| 52 Week Range 89.17 - 163.11 | Market Cap $2.35B |
| Shares Outstanding 15.52M | Public Float 11.46M |
| Beta 0.65 | Rev. Per Employee N/A |
| P/E Ratio 24.67 | EPS $6.55 |
| Yield 158.22% | Dividend $0.64 |
| EX-DIVIDEND DATE Dec 31, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 66.30K |
NHC Performance
| 1 Week | 12.90% | ||
| 1 Month | 24.51% | ||
| 3 Months | 27.05% | ||
| 1 Year | 62.10% | ||
| 5 Years | 153.56% |
NHC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
An error occurred while fetching the data.
SEC Filings for National Healthcare Corporation - NHC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for National Healthcare Corporation - NHC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Dec 30, 2025 | Brian F. Kidd SVP, CFO | 24,140 | Bona fide gift | 0.00 |
| Jun 6, 2025 | Richard A. LaRoche Director | 205,760 | Bona fide gift Non-derivative transaction at $104.69 per share | 21,541,014.40 |
| May 21, 2025 | Brian F. Kidd SVP, CFO | 23,714 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $108.61 per share | 2,575,577.54 |
| May 21, 2025 | Brian F. Kidd SVP, CFO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 7, 2025 | Stephen Flower Flatt CEO; Director | 57,579 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | B. Anderson Flatt Senior VP & CIO | 13,171 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Vicki L Dodson Sr.VP Patient Srvcs | 7,547 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Josh A. McCreary Senior VP & General Counsel | 7,524 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Robert Michael Ussery President & COO | 155,721 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Brian F. Kidd SVP, CFO | 13,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Timothy J Shelly Sr.VP Operations | 11,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Sandra Y. Trail Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Sandra Y. Trail Director | 7,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $69.19 per share | 518,925.00 |
| Feb 27, 2025 | Vicki L Dodson Sr.VP Patient Srvcs | 13,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Josh A. McCreary Senior VP & General Counsel | 13,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | B. Anderson Flatt Senior VP & CIO | 13,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Stephen Flower Flatt CEO; Director | 18,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Robert Michael Ussery President & COO | 15,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 21, 2025 | James Paul Abernathy Director | 4,010 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 21, 2025 | James Paul Abernathy Director | 35,023 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $71.64 per share | 2,509,047.72 |